These findings indicated that anti-PD1 treatment failed to reinvigorate exhausted CD8+PD1+ T cells to execute anti-tumor surveillance; instead, anti-PD1 endowed this T cell subset with enhanced effector signature and tissue-damaging potential. The gene discussed is PDCD1; the disease is neoplasm.